A polypeptide sustained-release microsphere composition for injection and its preparation method
By adding an acylation inhibitor and a PLGA matrix to semaglutide microspheres, long-acting sustained-release microspheres were prepared, solving the problem of acylation side reactions and achieving stable, sustained release and high bioavailability of semaglutide, while reducing the frequency of administration.
Patent Information
- Application Number
- CN202610386280.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-03-27
- Publication Date
- 2026-11-17
AI Technical Summary
Existing semaglutide extended-release formulations have acylation side effects, leading to incomplete release of the drug components, affecting bioavailability, and requiring high dosing frequency, which cannot meet the demand for long-acting extended release.
By adding acylation inhibitors such as L-histidine and poloxamer to smegglutide microspheres and combining them with PLGA as a biocompatible polymer matrix, an injectable polypeptide sustained-release microsphere composition was prepared, which inhibits acylation side reactions and achieves long-term sustained release.
This technology enables stable and sustained release of smegglutide in vivo for more than 60 days, reducing the frequency of administration and improving bioavailability and therapeutic efficacy.
Smart Images

Figure CN123101656A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical preparations, specifically relating to an injectable polypeptide sustained-release microsphere composition, a microsphere product containing the same, and methods for preparing them. Background Technology
[0002] Diabetes mellitus and its chronic complications have become a serious chronic non-communicable disease that significantly impacts human health and quality of life. Its pathological characteristics include impaired pancreatic β-cell function, insufficient insulin secretion, and an imbalance in glucagon secretion, leading to a chronic hyperglycemic state. Currently, there are various clinical treatments for diabetes, including oral hypoglycemic agents, insulin injections, and novel biological agents. However, traditional drugs suffer from unstable blood glucose control, high dosing frequency, and significant side effects (such as hypoglycemia, gastrointestinal discomfort, liver damage, and increased cardiovascular burden), which to some extent affect patient adherence and quality of life.
[0003] In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have become a research hotspot in the field of diabetes treatment due to their unique effects of glucose-dependent hypoglycemia, promotion of pancreatic β-cell protection, enhancement of insulin secretion, and inhibition of glucagon secretion. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists can not only effectively control blood glucose fluctuations, but also have multiple benefits such as weight loss and potential cardiovascular protection. However, currently marketed semaglutide products (such as Ozempic, Wegovy, and Rybelsus) are once-weekly formulations, which to some extent still cannot meet the clinical demand for longer-acting sustained-release and reduced dosing frequency.
[0004] Chinese patents CN104203266A and CN105963685A disclose the formulation composition and preparation process of oral preparations of smegglutide. However, regardless of whether the tablets or capsules are prepared, whether wet or dry granulation is used, and regardless of the excipients (including disintegrants, binders, lubricants, etc.) used, the longest duration is only one day, and the oral dose is as high as 14mg each time. Compared with other antidiabetic drugs that are administered once a week, there is no obvious advantage and the cost of disease treatment is significantly higher.
[0005] Chinese patent CN116473909A discloses an injectable semaglutide sustained-release formulation and its preparation method. This patent dissolves the active ingredient of a polypeptide drug in deionized water containing an aggregation inhibitor (e.g., N-(8-[2-hydroxybenzoyl]-amino)octanoate, i.e., NAC salt) and a drug protectant (e.g., polyethylene glycol, gelatin, glycerin, etc.) to form an internal aqueous phase. The pH of the internal aqueous phase is adjusted to promote the monomerization of the active ingredient of the polypeptide drug and maintain stability during the preparation of the sustained-release formulation. This patent only addresses the stability of semaglutide during the preparation process and does not address the stability during the microsphere release process.
[0006] In fact, in the preparation of various formulations containing peptide drug components using the biocompatible matrix PLGA as a material, the peptide drug components can bind to degraded or undegraded polymers through non-specific adsorption and ion interaction, resulting in acylation side reactions and forming peptide-PLGA peptide acyl adducts. This leads to incomplete release of the drug components and seriously affects bioavailability.
[0007] Chinese patent CN110090293A discloses a method for inhibiting the acylation side reaction of peptide drugs in PLGA microspheres. This method targets the most widely used industrial microsphere preparation method—the emulsion solvent evaporation method—and achieves long-term inhibition of the acylation side reaction between the peptide and the carrier by adding a special type of divalent metal salt during the re-emulsion preparation process. However, its release period is relatively short, and the acylation inhibition effect is difficult to assess.
[0008] Therefore, there is an urgent need to develop a new long-acting sustained-release formulation of semaglutide that can inhibit the acylation side reaction between semaglutide and the carrier / matrix, has a long release period, and achieves a stable and sustained release effect of the drug in vivo. Summary of the Invention
[0009] Through comprehensive analysis of the molecular structure of semaglutide and extensive experimentation, the inventors unexpectedly discovered that adding certain substances can effectively inhibit the acylation reaction between semaglutide and the biocompatible polymer matrix in semaglutide microspheres in vitro and in vivo. Furthermore, the microspheres can continuously release semaglutide in cynomolgus monkeys for more than 60 days, exhibiting high relative bioavailability. It only requires dosing once every 4 to 8 weeks, significantly reducing the dosing frequency for diabetic and obese patients, improving medication adherence, and enhancing treatment safety and efficacy.
[0010] The first aspect of the present invention provides an injectable polypeptide sustained-release microsphere composition, characterized in that the sustained-release microsphere composition comprises 2-15% semaglutide, 0.3-30% acylation inhibitor, and 55-97% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0011] In some embodiments, the biocompatible polymer matrix of the present invention is polylactic-co-glycolic acid copolymer (PLGA). In some embodiments, the PLGA is selected from PLGA with an LA:GA ratio of 50:50 to 75:25 and a weight-average molecular weight (Mw) of 20,000 to 60,000 Daltons; preferably, the PLGA is selected from the following: PLGA with an LA:GA ratio of 50:50 and a weight-average molecular weight (Mw) of 20,000 to 60,000 Daltons; PLGA with an LA:GA ratio of 55:45 and a Mw of 40,000 to 60,000 Daltons; PLGA with an LA:GA ratio of 65:35 and a Mw of 20,000 to 40,000 Daltons; and PLGA with an LA:GA ratio of 75:25 and a Mw of 20,000 to 50,000 Daltons.
[0012] In some embodiments, the acylation inhibitor of the present invention is selected from at least one of L-histidine, L-arginine, L-methionine, poloxamer, dextran, and hydroxyethyl starch. In some preferred embodiments, the acylation inhibitor of the present invention is selected from at least one of L-histidine, poloxamer, dextran, and hydroxyethyl starch. In some more preferred embodiments, the acylation inhibitor of the present invention is selected from a combination of L-histidine and poloxamer, a combination of dextran, L-histidine, and poloxamer, dextran, and hydroxyethyl starch. In some even more preferred embodiments, the acylation inhibitor of the present invention is selected from a combination of L-histidine and poloxamer, or hydroxyethyl starch. In some embodiments, the acylation inhibitor of the present invention is selected from at least one of L-histidine, L-arginine, L-methionine, poloxamer 188, poloxamer 407, dextran 20, dextran 40, dextran 70, hydroxyethyl starch 130 / 0.4, and hydroxyethyl starch 200 / 0.5. In some preferred embodiments, the acylation inhibitor of the present invention is selected from at least one of L-histidine, poloxamer 188, poloxamer 407, dextran 20, dextran 40, dextran 70, hydroxyethyl starch 130 / 0.4, and hydroxyethyl starch 200 / 0.5. In one preferred embodiment, the acylation inhibitor of the present invention is selected from at least one of L-histidine, poloxamer 188, dextran 70, and hydroxyethyl starch 130 / 0.4. In a more preferred embodiment, the acylation inhibitor of the present invention is a combination of dextran 70, L-histidine, and poloxamer 188. In a further preferred embodiment, the acylation inhibitor of the present invention is a combination of both L-histidine and poloxamer 188. In a further preferred embodiment, the acylation inhibitor of the present invention is selected from hydroxyethyl starch 130 / 0.4 and hydroxyethyl starch 200 / 0.5.
[0013] In some embodiments, the weight ratio of each acylation inhibitor of the present invention to smegglutinin is 0.1 to 2:1.
[0014] In some embodiments, the weight ratio of each acylation inhibitor of the present invention to smegglutinin is 0.2 to 0.8:1, preferably 0.25 to 0.5:1; in these embodiments, the acylation inhibitor is selected from at least one of L-histidine, L-arginine, L-methionine, and poloxamer; preferably at least one of L-histidine and poloxamer; more preferably a combination of L-histidine and poloxamer 188.
[0015] In some embodiments, the weight ratio of the acylation inhibitor to semaglutide of the present invention is 0.5 to 2:1. In some embodiments, the weight ratio of the acylation inhibitor to semaglutide is 0.6 to 1.5:1, more preferably 0.6 to 1.2:1; in these embodiments, the acylation inhibitor is selected from at least one of dextran and hydroxyethyl starch; preferably hydroxyethyl starch; more preferably hydroxyethyl starch 130 / 0.4 or hydroxyethyl starch 200 / 0.5.
[0016] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, preferably 3-7%, more preferably 3-6%, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0017] In some embodiments, the sustained-release microsphere composition of the present invention comprises 0.5-20%, preferably 1-14%, more preferably 2-10%, of an acylation inhibitor based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0018] In some embodiments, the sustained-release microsphere composition of the present invention comprises 65-95%, preferably 70-92%, more preferably 80-92%, of a biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0019] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.5-20% acylation inhibitor, and 65-95% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0020] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.5-20% acylation inhibitor, and 70-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0021] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-14% acylation inhibitor, and 70-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0022] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-14% acylation inhibitor, and 80-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0023] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-14% acylation inhibitor, and 65-95% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0024] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-14% acylation inhibitor, and 70-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0025] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 2-10% acylation inhibitor, and 65-95% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0026] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 2-10% acylation inhibitor, and 70-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0027] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 2-10% acylation inhibitor, and 80-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0028] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-14% acylation inhibitor, and 65-95% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0029] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 2-10% acylation inhibitor, and 70-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0030] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 2-10% acylation inhibitor, and 80-92% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0031] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.3-30% hydroxyethyl starch, and 65-95% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0032] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-14% hydroxyethyl starch, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0033] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 2-10% hydroxyethyl starch, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0034] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-14% hydroxyethyl starch, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0035] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 2-10% hydroxyethyl starch, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0036] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 4-9.5% hydroxyethyl starch, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0037] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 2-10% hydroxyethyl starch, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0038] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 4-9.5% hydroxyethyl starch, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0039] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.3-8% histidine, 0.3-8% poloxamer, and 65-95% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0040] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.5-7% histidine, 0.5-7% poloxamer, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0041] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-5% histidine, 1-5% poloxamer, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0042] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-5% histidine, 1.5-5% poloxamer, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0043] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 0.3-8% histidine, 0.3-8% poloxamer, and 65-95% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0044] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 0.5-7% histidine, 0.5-7% poloxamer, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0045] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1-5% poloxamer, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0046] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1.5-5% poloxamer, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0047] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1.5-5% poloxamer, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0048] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.3-30% dextran, and 65-95% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0049] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-14% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0050] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 2-10% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0051] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-14% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0052] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 2-10% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0053] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 4-9.5% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0054] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 2-10% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0055] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 4-9.5% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0056] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 0.3-8% histidine, 0.3-8% poloxamer, 0.3-8% dextran, and 65-95% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0057] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-5% histidine, 1-5% poloxamer, 2-7% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0058] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-5% histidine, 1-5% poloxamer, 2-7% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0059] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-10% smegglutinin, 1-5% histidine, 1.5-5% poloxamer, 2-7% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0060] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-7% smegglutinin, 1-5% histidine, 1-5% poloxamer, 2-10% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0061] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 0.3-8% histidine, 0.3-8% poloxamer, 0.3-8% dextran, and 65-95% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0062] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 0.5-7% histidine, 0.5-7% poloxamer, 2-7% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0063] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1-5% poloxamer, 2-7% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0064] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1.5-5% poloxamer, 2-7% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0065] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1-5% poloxamer, 2-7% dextran, and 70-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0066] In some embodiments, the sustained-release microsphere composition of the present invention comprises 3-6% smegglutinin, 1-5% histidine, 1.5-5% poloxamer, 2-7% dextran, and 80-92% PLGA, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0067] In some preferred embodiments, the sustained-release microsphere composition of the present invention is selected from any of the following formulations: Smegglutide 5.7%, acylation inhibitor 5.7%, PLGA 88.6%; Smegglutide 5.8%, acylation inhibitor 3.9%, PLGA 90.3%; Smegglutide 4.6%, acylation inhibitor 9.3%, PLGA 86.1%; Smegglutinin 4.6%, hydroxyethyl starch 9.3%, PLGA 86.1%; Smegglutide 4.6%, dextran 9.3%, PLGA 86.1%; Smegglutide 5.7%, dextran 5.7%, PLGA 88.6%; Smegglutinin 5.8%, L-histidine 1.6%, poloxamer 2.3%, PLGA 90.3%; Each is based on the total weight of the injectable polypeptide sustained-release microsphere composition.
[0068] In all embodiments of the invention, hydroxyethyl starch is any type of hydroxyethyl starch, preferably hydroxyethyl starch 130 / 0.4 or hydroxyethyl starch 200 / 0.5. In all embodiments of the invention, dextran is any type of dextran, preferably dextran 20, dextran 40, or dextran 70. In all embodiments of the invention, poloxamer is any type of poloxamer, preferably poloxamer 188 or poloxamer 407.
[0069] A second aspect of the present invention provides a sterile microsphere product comprising the injectable polypeptide sustained-release microsphere composition and a desiccant according to the first aspect of the present invention.
[0070] In some embodiments, the desiccant contained in the sterile microsphere product of the present invention is selected from mannitol, sorbitol, lactose, trehalose, and polyethylene glycol, preferably mannitol.
[0071] In some embodiments, the amount of the desiccant is 10-30% of the mass of the injectable polypeptide sustained-release microsphere composition, preferably 15-25%, more preferably 18-22%.
[0072] In some embodiments, the particle size D50 of the sterile microsphere product of the present invention is 10~150 μm, preferably 20~130 μm, more preferably 30~110 μm; even more preferably 40~90 μm, and most preferably 50~70 μm.
[0073] In some embodiments, the encapsulation rate of the sterile microsphere product of the present invention is 75-99%, preferably 80-99%, and more preferably 85-99%.
[0074] In some embodiments, the polypeptide sustained-release microsphere composition of the present invention and the sterile microsphere product of the present invention can stably and continuously release in vivo and in vitro, with an in vivo sustained-release period of up to 30-60 days and a relative bioavailability of 20-50%.
[0075] A third aspect of the present invention provides an injectable polypeptide sustained-release microsphere composition, characterized in that it is prepared by the following method: A) Dissolve smegglutinin and the acylation inhibitor in deionized water to obtain a true solution; B) Dissolve the biocompatible polymer matrix in an organic solvent to form an oil phase solution, and then add the true solution obtained in step A) to the oil phase solution, and process it to form a heterogeneous solution; C) Add a phase separating agent to the heterogeneous solution obtained in step B), and form a phase-separated phase containing a soft state under stirring conditions. Transfer the phase-separated phase to a curing system for curing and washing to obtain wet microspheres. D) The microspheres obtained in step C) are dried at a controlled temperature using airflow drying, vacuum drying, or a combination of both to obtain a polypeptide sustained-release microsphere composition.
[0076] In some embodiments, in step B), the organic solvent is selected from one of dichloromethane, trichloromethane, ethyl acetate, or any combination thereof. Preferably, the organic solvent in step B) is selected from dichloromethane.
[0077] In some embodiments, in step C), the phase separating agent is selected from one or more combinations of dimethicone oils with a viscosity in the range of 100 to 1000 cSt.
[0078] In some embodiments, in step C), the curing system is selected from one or more of n-heptane, water, Span 80, and anhydrous ethanol. In some embodiments, in step C), the curing system is selected from n-heptane, or a combination of n-heptane / water / Span 80. In some specific embodiments, the weight ratio of n-heptane / water / Span 80 is 72.5:27:0.5.
[0079] In some embodiments, the amount of smegglutinin used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 2-15%, the amount of acylation inhibitor is 0.3-30%, and the amount of biocompatible polymer matrix is 55-97%, based on the total weight of the three components.
[0080] In some embodiments, the weight ratio of the acylation inhibitor to smegglutinin used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 0.1 to 2:1.
[0081] In some embodiments, the weight ratio of each acylation inhibitor to semaglutide used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 0.2 to 0.8:1, preferably 0.25 to 0.5:1; in these embodiments, the acylation inhibitor is selected from at least one of L-histidine, L-arginine, L-methionine, and poloxamer; preferably at least one of L-histidine and poloxamer; more preferably a combination of L-histidine and poloxamer 188.
[0082] In other embodiments, the weight ratio of the acylation inhibitor to semaglutide used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 0.5 to 2:1. In some embodiments, the weight ratio of the acylation inhibitor to semaglutide is 0.6 to 1.5:1, more preferably 0.6 to 1.2:1; in these embodiments, the acylation inhibitor is selected from at least one of dextran and hydroxyethyl starch; preferably hydroxyethyl starch; more preferably hydroxyethyl starch 130 / 0.4 or hydroxyethyl starch 200 / 0.5.
[0083] In some embodiments, the amount of smegglutinin used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 3-10%, preferably 3-7%, more preferably 3-6%, based on the total weight of smegglutinin, acylation inhibitor and biocompatible polymer matrix.
[0084] In some embodiments, the acylation inhibitor used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 0.5-20%, preferably 1-14%, more preferably 2-10%, based on the total weight of smegglutinin, the acylation inhibitor and the biocompatible polymer matrix.
[0085] In some embodiments, the biocompatible polymer matrix used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention is 65-95%, preferably 70-92%, more preferably 80-92%, based on the total weight of smegglutinin, acylation inhibitor and biocompatible polymer matrix.
[0086] In some embodiments, the proportions of materials used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention are selected from one of the following, based on the total weight of smegglutinin, acylation inhibitor, and biocompatible polymer matrix: Smegglutinin 3-10%, acylation inhibitor 0.5-20%, biocompatible polymer matrix 65-95%; Smegglutinin 3-10%, acylation inhibitor 0.5-20%, biocompatible polymer matrix 70-92%; Smegglutinin 3-10%, acylation inhibitor 1-14%, biocompatible polymer matrix 70-92%; Smegglutinin 3-10%, acylation inhibitor 1-14%, biocompatible polymer matrix 80-92%; Smegglutinin 3-7%, acylation inhibitor 1-14%, biocompatible polymer matrix 65-95%; Smegglutinin 3-7%, acylation inhibitor 1-14%, biocompatible polymer matrix 70-92%; Smegglutinin 3-7%, acylation inhibitor 2-10%, biocompatible polymer matrix 65-95%; Smegglutinin 3-7%, acylation inhibitor 2-10%, biocompatible polymer matrix 70-92%; Smegglutinin 3-7%, acylation inhibitor 2-10%, biocompatible polymer matrix 80-92%; Smegglutinin 3-6%, acylation inhibitor 1-14%, biocompatible polymer matrix 65-95%; Smegglutinin 3-6%, acylation inhibitor 2-10%, biocompatible polymer matrix 70-92%; Smegglutinin 3-6%, acylation inhibitor 2-10%, biocompatible polymer matrix 80-92%; Smegglutinin 3-10%, hydroxyethyl starch 0.3-30%, PLGA 65-95%; Smegglutinin 3-10%, hydroxyethyl starch 1-14%, PLGA 70-92%; Smegglutinin 3-10%, hydroxyethyl starch 2-10%, PLGA 80-92%; Smegglutinin 3-7%, hydroxyethyl starch 1-14%, PLGA 70-92%; Smegglutinin 3-7%, hydroxyethyl starch 2-10%, PLGA 70-92%; Smegglutinin 3-7%, hydroxyethyl starch 4-9.5%, PLGA 80-92%; Smegglutinin 3-6%, hydroxyethyl starch 2-10%, PLGA 80-92%; Smegglutinin 3-6%, hydroxyethyl starch 4-9.5%, PLGA 80-92%; Smegglutinin 3-10%, histidine 0.3-8%, poloxamer 0.3-8%, PLGA 65-95%; Smegglutinin 3-10%, histidine 0.5-7%, poloxamer 0.5-7%, PLGA 70-92%; Smegglutinin 3-7%, histidine 1-5%, poloxamer 1-5%, PLGA 70-92%; Smegglutinin 3-7%, histidine 1-5%, poloxamer 1.5-5%, PLGA 80-92%; Smegglutinin 3-6%, histidine 0.3-8%, poloxamer 0.3-8%, PLGA 65-95%; Smegglutinin 3-6%, histidine 0.5-7%, poloxamer 0.5-7%, PLGA 70-92%; Smegglutinin 3-6%, histidine 1-5%, poloxamer 1-5%, PLGA 80-92%; Smegglutinin 3-6%, histidine 1-5%, poloxamer 1.5-5%, PLGA 70-92%; Smegglutinin 3-6%, histidine 1-5%, poloxamer 1.5-5%, PLGA 80-92%; Smegglutide 3-10%, dextran 0.3-30%, PLGA 65-95%; Smegglutinin 3-10%, dextran 1-14%, PLGA 70-92%; Smegglutinin 3-10%, dextran 2-10%, PLGA 80-92%; Smegglutinin 3-7%, dextran 1-14%, PLGA 70-92%; Smegglutinin 3-7%, dextran 2-10%, PLGA 70-92%; Smegglutide 3-7%, dextran 4-9.5%, PLGA 80-92%; Smegglutinin 3-6%, dextran 2-10%, PLGA 80-92%; Smegglutide 3-6%, dextran 4-9.5%, PLGA 80-92%; Smegglutide 3-10%, histidine 0.3-8%, poloxamer 0.3-8%, dextran 0.3-8%, PLGA 65-95%; Smegglutide 3-10%, histidine 1-5%, poloxamer 1-5%, dextran 2-7%, PLGA 70-92%; Smegglutinin 3-10%, histidine 1-5%, poloxamer 1-5%, dextran 2-7%, PLGA 80-92%; Smegglutide 3-10%, histidine 1-5%, poloxamer 1.5-5%, dextran 2-7%, PLGA 80-92%; Smegglutide 3-7%, histidine 1-5%, poloxamer 1-5%, dextran 2-10%, PLGA 70-92%; Smegglutide 3-6%, histidine 0.3-8%, poloxamer 0.3-8%, dextran 0.3-8%, PLGA 65-95%; Smegglutide 3-6%, histidine 0.5-7%, poloxamer 0.5-7%, dextran 2-7%, PLGA 70-92%; Smegglutide 3-6%, histidine 1-5%, poloxamer 1-5%, dextran 2-7%, PLGA 80-92%; Smegglutide 3-6%, histidine 1-5%, poloxamer 1.5-5%, dextran 2-7%, PLGA 70-92%; Smegglutide 3-6%, histidine 1-5%, poloxamer 1-5%, dextran 2-7%, PLGA 70-92%; Smegglutide 3-6%, histidine 1-5%, poloxamer 1.5-5%, dextran 2-7%, PLGA 80-92%.
[0087] In some preferred embodiments, the proportions of materials used in the preparation method of the injectable polypeptide sustained-release microsphere composition of the present invention are selected from one of the following, based on the total weight of smegglutinin, acylation inhibitor, and biocompatible polymer matrix: Smegglutide 5.7%, acylation inhibitor 5.7%, PLGA 88.6%; Smegglutide 5.8%, acylation inhibitor 3.9%, PLGA 90.3%; Smegglutide 4.6%, acylation inhibitor 9.3%, PLGA 86.1%; Smegglutinin 4.6%, hydroxyethyl starch 9.3%, PLGA 86.1%; Smegglutide 4.6%, dextran 9.3%, PLGA 86.1%; Smegglutide 5.7%, dextran 5.7%, PLGA 88.6%; Smegglutide 5.8%, L-histidine 1.6%, poloxamer 2.3%, PLGA 90.3%.
[0088] The acylation inhibitor and biocompatible polymer matrix used in the third aspect of the present invention have the same characteristics as the acylation inhibitor and biocompatible polymer matrix described in the first aspect of the present invention.
[0089] A fourth aspect of the present invention provides a sterile microsphere product comprising the injectable polypeptide sustained-release microsphere composition described in the first or third aspect of the present invention and a desiccant, characterized in that it is prepared by a step comprising the following method: mixing the injectable polypeptide sustained-release microsphere composition with a desiccant.
[0090] In some embodiments of the fourth aspect of the invention, the amount of drying and protective agent used in the powder mixing step is 10-30% of the mass of the injectable polypeptide sustained-release microsphere composition used, preferably 15-25%, more preferably 18-22%.
[0091] The desiccant used in the fourth aspect of the present invention has the same characteristics as the desiccant described in the second aspect of the present invention.
[0092] The sterile microsphere product of the fourth aspect of the present invention is the same as the sterile microsphere product described in the second aspect of the present invention in terms of particle size, encapsulation efficiency, and in vitro and in vivo release.
[0093] The fifth aspect of the present invention provides the use of the injectable polypeptide sustained-release microsphere composition described in the first and third aspects of the present invention or the sterile microsphere product described in the second and fourth aspects of the present invention in the preparation of medicaments for treating diseases such as diabetes and obesity.
[0094] The polypeptide sustained-release microsphere composition and sterile microsphere product of the present invention have the following advantages: 1) The microspheres have a moderate drug loading capacity and controllable particle size, ensuring a continuous and stable sustained-release effect in vivo and in vitro; 2) The microspheres have a sustained-release period of more than 60 days in the body, which significantly extends the dosing interval compared to the weekly dosing mode of existing products; 3) The added acylation inhibitor can effectively inhibit the acylation reaction between smegglutinin and PLGA, improve bioavailability, and reduce the risk of adverse reactions; 4) The improved phase separation preparation technology has a stable preparation process and is suitable for large-scale production. Attached Figure Description
[0095] Figure 1 These are scanning electron microscope images of the microspheres prepared in Example 1.
[0096] Figure 2 These are the in vitro release curves of the microsphere products prepared in each embodiment.
[0097] Figure 3 The pharmacokinetic (PK) curves of the microsphere products prepared in each example in SD rats are shown.
[0098] Figure 4 These are the PK curves of the microsphere products prepared in each embodiment in cynomolgus monkeys.
[0099] Figure 5 This is a sequence analysis map of [lactic acid-histidine]-smegglutinin.
[0100] Figure 6 This is a sequence analysis map of [glycolic acid-histidine]-smegglutinin. Detailed Implementation
[0101] The present invention will be further illustrated below through specific embodiments. It should be understood that the embodiments of the present invention are merely provided for illustrative purposes and are not intended to limit the present invention. Improvements, modifications, substitutions, and variations of the following embodiments under the premise of the technical solutions of the present invention all fall within the protection scope of the present invention.
[0102] Sustained-release microspheres are tiny spherical entities formed by dissolving or dispersing drugs in polymeric materials. They are spherical or near-spherical in shape and are generally prepared as suspensions for injection or oral administration. The particle size of microspheres typically ranges from 1 to 500 μm, with some as small as a few nanometers and others as large as 800 μm.
[0103] Unless otherwise stated, all process operations and steps are performed at room temperature. Room temperature, in this document, refers to 15 to 35°C, preferably 20 to 30°C.
[0104] In this document, unless otherwise stated, all “%” or “percentage” means “percentage by weight” or “weight percentage”.
[0105] In this article, when "%" or "weight percentage" is mentioned, it means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of a given value or range. For example, the range "10~20%" means including the range "7~26%"; that is, the range "10~20%" includes the range between the lower limit of 7% and the upper limit of 26%. As another example, the value "10%" includes the range between "7~13%".
[0106] The control group of semaglutide injection was formulated according to the OZEMPIC formula published by Novo Nordisk and contained the following components: 1.34 mg semaglutide per 1 mL of solution, and the following inactive ingredients: 1.42 mg disodium hydrogen phosphate dihydrate, 14 mg propylene glycol, 5.5 mg phenol and water for injection, with the pH adjusted to 7.4 using hydrochloric acid or sodium hydroxide.
[0107] Detection method: Scanning electron microscope: The microspheres prepared in the example were fixed on the tape and their morphology was observed using a scanning electron microscope (×1000) after metal sputtering.
[0108] HPLC method for drug loading detection: Mobile phase: water-acetonitrile-trifluoroacetic acid (52:48:0.1); isocratic, run time 12 min, flow rate: 0.6 ml / min, column temperature: 50 ℃, detection wavelength 214 nm, injection volume 40 μL, sample chamber temperature: 10 ℃.
[0109] Release curve HPLC detection method: Water-acetonitrile-trifluoroacetic acid (52:48:0.1) was used as the mobile phase, with isocratic elution, column temperature of 50℃, flow rate of 0.6 ml / min, detection wavelength of 214 nm, injection volume of 20 μl, and sample chamber temperature of 10℃.
[0110] Assay: Accurately measure the test solution and reference solution, inject them separately into the liquid chromatograph, and record the chromatograms. Mass spectrometry detection method:
[0111] Example 1 0.3g of semaglutide was dissolved in 1.3g of water for injection to form an aqueous phase; 4.65g of PLGA (LA:GA = 55:45; Mw 40000~60000 Daltons) was dissolved in 200g of dichloromethane to obtain an oil phase; the aqueous phase was added to the oil phase, and a primary emulsion was obtained by using a Sonics & Materials VCX750 ultrasonic cell disruptor with an ultrasonic intensity of 40% and an ultrasonic time of 10 minutes; 160g of 1000cSt dimethicone and 200g of 350cSt dimethicone were added to the emulsion sequentially and stirred continuously to obtain a phase-separated phase; the phase-separated phase was transferred to 1820g of curing solvent (n-heptane / water / Span 80, weight ratio 72.5:27:0.5) for curing, and washed with 500g of n-heptane to obtain wet semaglutide microspheres. All the above steps were carried out under controlled temperature conditions of 20℃. Smegglutide microspheres were obtained by air-drying. After weighing, mannitol was added at 20% of the mass of the microspheres. The microspheres were then vacuum dried to obtain the final Smegglutide microsphere product. HPLC analysis showed that the Smegglutide content was 4.53%, the D50 was 62 μm, and the encapsulation rate was 93%.
[0112] Example 2 Weigh 0.27g of smegglutinin and 0.08g of sucrose and dissolve them in 1.3g of water for injection to form an aqueous phase; weigh 4.30g of PLGA (LA:GA = 50:50; Mw 20000~60000 Daltons) and dissolve it in 200g of dichloromethane to obtain an oil phase; add the aqueous phase to the oil phase, and use a Sonics & Materials VCX750 ultrasonic cell disruptor, set the ultrasonic intensity to 40%, and sonicate for 10 minutes to obtain the colostrum; add 160g of 1000cSt dimethicone and 200g of [unclear text - possibly a specific ingredient or product] to the emulsion sequentially. 350 cSt dimethicone was continuously stirred to obtain a phase-separated phase. This phase was then transferred to 1820 g of curing solvent (n-heptane / water / Span 80, weight ratio 72.5:27:0.5) for curing. The microspheres were washed with 500 g of n-heptane to obtain wet semaglutide microspheres. All steps were performed at a controlled temperature of 20°C. The microspheres were then dried by airflow to obtain semaglutide microspheres. After weighing, mannitol was added at 19.8% of the microsphere mass, followed by vacuum drying to obtain the final semaglutide microsphere product. HPLC analysis showed a semaglutide content of 3.85%, a D50 of 58 μm, and an encapsulation efficiency of 83%.
[0113] Example 3 0.3g of semaglutide and 0.3g of dextran 70 were weighed and dissolved in water for injection to form an aqueous phase. 4.65g of PLGA (LA:GA = 55:45; Mw 40000~60000 Daltons) was weighed and dissolved in 200g of dichloromethane to obtain an oil phase. The aqueous phase was added to the oil phase, and a primary emulsion was obtained by using a Sonics & Materials VCX750 ultrasonic cell disruptor with an ultrasonic intensity of 40% and an ultrasonic time of 10 minutes. 160g of 1000cSt dimethicone and 200g of 350cSt dimethicone were added to the emulsion sequentially and stirred continuously to obtain a phase-separated phase. The phase-separated phase was transferred to 1820g of curing solvent (n-heptane / water / Span 80, weight ratio 72.5:27:0.5) for curing, and washed with 500g of n-heptane to obtain wet semaglutide microspheres. All the above steps were carried out under controlled temperature conditions of 20℃. Smegglutide microspheres were obtained by air-drying. After weighing, mannitol was added at 18.8% of the mass of the microspheres. The microspheres were then dried under vacuum to obtain the final Smegglutide microsphere product. HPLC analysis showed that the Smegglutide content was 3.4%, the D50 was 55 μm, and the encapsulation rate was 75%.
[0114] Example 4 0.3g of semaglutide was dissolved in 1.3g of water for injection, and then 0.08g of L-histidine and 0.12g of poloxamer 188 were added to form an aqueous phase. 4.65g of PLGA (LA:GA ratio 55:45; Mw 40000~60000 Daltons) was dissolved in 200g of dichloromethane to obtain an oil phase. The aqueous phase was added to the oil phase and dispersed under high shear (shear speed 20000rpm, shear time 5 minutes) to obtain a primary emulsion. 360g of 350cSt dimethicone was added to the emulsion and stirred continuously to obtain a phase-separated phase. The phase-separated phase was transferred to 1820g of curing solvent (n-heptane / water / Span 80, weight ratio 72.5:27:0.5) for curing, and washed with 500g of n-heptane to obtain wet semaglutide microspheres. All the above steps were carried out under controlled temperature of 20℃. Smegglutide microspheres were obtained by air-drying. After weighing, mannitol was added at 20% of the mass of the microspheres. The microspheres were then dried under vacuum to obtain the final Smegglutide microsphere product. HPLC analysis showed that the Smegglutide content was 4.11%, the D50 was 60 μm, and the encapsulation rate was 89%.
[0115] Example 5 0.25g of smegglutide and 0.5g of dextran 70 were dissolved in 2.4g of water for injection to form an aqueous phase; 4.65g of PLGA (LA:GA = 55:45; Mw 40000~60000 Daltons) were dissolved in 200g of dichloromethane to obtain an oil phase; the aqueous phase was added to the oil phase and dispersed under high shear (shear speed 20000rpm, shear time 5min) to obtain a primary emulsion; 360g of 350cSt dimethicone was added to the emulsion and stirred continuously to obtain a phase-separated phase; the phase-separated phase was transferred to 3500g of curing solvent (n-heptane) for curing, and washed with 500g of n-heptane to obtain wet smegglutide microspheres. All the above steps were carried out under controlled temperature of 20℃. Smegglutide microspheres were obtained by air-drying. After weighing, mannitol was added at 20.2% of the mass of the microspheres. The microspheres were then dried under vacuum to obtain the final Smegglutide microsphere product. HPLC analysis showed that the Smegglutide content was 3.34%, the D50 was 62 μm, and the encapsulation rate was 91%.
[0116] Example 6 0.25g of smegglutide and 0.5g of hydroxyethyl starch 130 / 0.4 were dissolved in 1.7g of water for injection to form an aqueous phase; 4.65g of PLGA (LA:GA = 55:45; Mw 40000~60000 Daltons) were dissolved in 200g of dichloromethane to obtain an oil phase; the aqueous phase was added to the oil phase and dispersed under high shear (shear speed 20000rpm, shear time 5min) to obtain a primary emulsion; 360g of 350cSt dimethicone was added to the emulsion and stirred continuously to obtain a phase-separated phase; the phase-separated phase was transferred to 3500g of curing solvent (n-heptane) for curing, and washed with 500g of n-heptane to obtain wet smegglutide microspheres. All the above steps were carried out under controlled temperature of 20℃. Smegglutide microspheres were obtained by air-drying. After weighing, mannitol was added at 22% of the mass of the microspheres. The microspheres were then dried under vacuum to obtain the final Smegglutide microsphere product. HPLC analysis showed that the Smegglutide content was 3.23%, the D50 was 69 μm, and the encapsulation rate was 90%.
[0117] Example 7: In vitro release study and acylation comparison The microspheres obtained in Examples 1 to 6 were tested: Approximately 50 mg of microspheres were accurately weighed and placed in a 100 ml sealed reagent bottle. 50 ml of release medium composed of ammonium chloride-triethylamine solution + 2.1% SDS + 0.5% Proclin 950 was added. The bottle was sealed and mixed thoroughly. Six parallel samples were prepared. Each sealed reagent bottle was placed in a water bath at 37℃±0.5℃ and allowed to stand. Samples were taken at 2 hours, 1 day, 4 days, 7 days, 10 days, 14 days, 17 days, 21 days, 24 days, 28 days, 31 days, and 35 days. Before sampling, the bottle was slowly rotated to ensure uniform suspension. After standing, the microspheres were allowed to settle completely. 1 ml of the sample was accurately measured, and an equal volume of isothermal release medium was added. The sample solution was centrifuged at 10,000 rpm for 5 minutes. The supernatant was used as the test solution for HPLC analysis. The in vitro release curves plotted based on the detection results are shown below. Figure 2 As shown. Simultaneously, the molecular weight and sequence of acylation-related substances in samples taken on day 35 were determined by mass spectrometry analysis, and the results are shown below. Figure 5 , 6 As shown below, the ratio of smegglutinin to acylation-related substances in the in vitro release solution of each embodiment is as follows.
[0118] Table 1. Comparison of smegglutinin and acylated products after 35 days of in vitro release for each example.
[0119] As shown in Table 1, after 35 days of release of conventional samples under simulated body fluid conditions, the effect of adding sucrose as an acylation inhibitor in Example 2 was generally weak, showing a similar degree of acylation inhibition to Example 1 without the addition of an acylation inhibitor, reducing acylation-related substances by only about 2%. However, Examples 3, 4, 5, and 6, after adding L-histidine / poloxam 188, dextran 70, and hydroxyethyl starch 130 / 0.4 as acylation inhibitors, showed better in vitro acylation inhibition capabilities, reducing the generation of acylation-related substances by 10-27%.
[0120] Example 8: In vivo pharmacokinetic study (1) SD rats were selected for in vivo pharmacokinetic studies. Blood samples were collected and blood drug concentrations were determined according to the following administration regimen: Injection group (control group): The dosage was 0.1 mg / kg. Blood samples were collected before administration, at 0.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, and 96 h. Results are shown below. Figure 3 ; Microsphere group (microsphere products prepared in Examples 1 to 6): The dosage was 4 mg / kg. Blood was collected before administration (0 min) and at 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h (D1), 48 h (D2), 72 h (D3), 120 h (D5), 168 h (D7), 240 h (D10), 288 h (D12), 360 h (D15), 432 h (D18), 504 h (D21), 576 h (D24), 672 h (D28), 744 h (D31), 816 h (D34), and 888 h (D37). Results are shown in […]. Figure 3 .
[0121] (2) Cynomolgus monkeys were selected for in vivo pharmacokinetic studies. Blood samples were collected and blood drug concentrations were determined according to the following administration regimen: Injection group (control group): The dosage was 0.1 mg / kg. Blood samples were collected before administration, at 0.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, and 96 h. Results are shown below. Figure 4 ; Microsphere group (microsphere products prepared in Examples 1, 4, 5, and 6): The dosage was 4 mg / kg. Blood samples were collected before administration and at 2 h, 6 h, 12 h, 24 h, 48 h, 72 h, 96 h, 120 h (D5), 144 h (D6), 168 h (D7), 216 h (D9), 264 h (D11), D13, D16, D19, D22, D25, D28, D31, D34, D37, D40, D43, D46, D49, D52, D56, and D60. Results are shown in […]. Figure 4 .
[0122] Example 9: Relative Bioavailability Study Methods for calculating relative bioavailability in cynomolgus monkeys: Formula: F=AUC T ·D R / AUC R ·D T ×100% In the formula, AUC represents the area under the blood drug concentration-time curve, the subscripts T and R represent the test formulation and the reference formulation administered extravascularly, respectively, and D represents the dose.
[0123] Plot the area under the pharmacokinetic curves of the products in Examples 1, 4, 5, 6 and the injection group in cynomolgus monkeys, and calculate the relative bioavailability.
[0124] Table 2 Comparison of bioavailability of products obtained from each embodiment after 60 days of sampling
[0125] Summary: The relative bioavailability of Example 1, which did not contain an acylation inhibitor, was only 9% when normalized to the injectable solution. However, the products of Examples 4, 5, and 6, which contained acylation inhibitors such as L-histidine / poloxam 188, dextran 70, and hydroxyethyl starch 130 / 0.4, respectively, showed an increase of approximately 2 to 6 times in relative bioavailability.
Claims
1. A polypeptide sustained-release microsphere composition for injection, characterized in that, The sustained-release microsphere composition comprises 2-15% smegglutinin, 0.3-30% acylation inhibitor, and 55-97% biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
2. The injectable polypeptide sustained-release microsphere composition according to claim 1, characterized in that, The biocompatible polymer matrix is polylactic acid-glycolic acid copolymer (PLGA); preferably, the PLGA is selected from PLGA with an LA:GA ratio of 50:50 to 75:25 and a weight-average molecular weight (Mw) of 20,000 to 60,000 Daltons; more preferably, the PLGA is selected from the following: PLGA with an LA:GA ratio of 50:50 and a weight-average molecular weight (Mw) of 20,000 to 60,000 Daltons, PLGA with an LA:GA ratio of 55:45 and a Mw of 40,000 to 60,000 Daltons, PLGA with an LA:GA ratio of 65:35 and a Mw of 20,000 to 40,000 Daltons, and PLGA with an LA:GA ratio of 75:25 and a Mw of 20,000 to 50,000 Daltons.
3. The injectable polypeptide sustained-release microsphere composition according to claim 1 or 2, characterized in that, The acylation inhibitor is selected from at least one of L-histidine, L-arginine, L-methionine, poloxamer, dextran, and hydroxyethyl starch; preferably selected from at least one of L-histidine, L-arginine, L-methionine, poloxamer 188, poloxamer 407, dextran 20, dextran 40, dextran 70, hydroxyethyl starch 130 / 0.4, and hydroxyethyl starch 200 / 0.
5.
4. The injectable polypeptide sustained-release microsphere composition according to any one of claims 1 to 3, characterized in that, The weight ratio of the acylation inhibitor to smegglutinin is 0.1~2:
1.
5. The injectable polypeptide sustained-release microsphere composition according to any one of claims 1 to 4, characterized in that, The sustained-release microsphere composition contains 3-10% smegglutinin, preferably 3-7%, more preferably 3-6%, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
6. The injectable polypeptide sustained-release microsphere composition according to any one of claims 1 to 5, characterized in that, The sustained-release microsphere composition contains 0.5-20%, preferably 1-14%, more preferably 2-10%, of an acylation inhibitor based on the total weight of the injectable polypeptide sustained-release microsphere composition.
7. The injectable polypeptide sustained-release microsphere composition according to any one of claims 1 to 6, characterized in that, The sustained-release microsphere composition comprises 65-95%, preferably 70-92%, more preferably 80-92%, of a biocompatible polymer matrix, based on the total weight of the injectable polypeptide sustained-release microsphere composition.
8. The injectable polypeptide sustained-release microsphere composition according to any one of claims 1 to 7, characterized in that, The sustained-release microsphere composition is selected from any of the following formulations: Smegglutinin 3-10%, acylation inhibitor 0.5-20%, biocompatible polymer matrix 65-95%; Smegglutinin 3-10%, acylation inhibitor 0.5-20%, biocompatible polymer matrix 70-92%; Smegglutinin 3-10%, acylation inhibitor 1-14%, biocompatible polymer matrix 70-92%; Smegglutinin 3-10%, acylation inhibitor 1-14%, biocompatible polymer matrix 80-92%; Smegglutinin 3-7%, acylation inhibitor 1-14%, biocompatible polymer matrix 65-95%; Smegglutinin 3-7%, acylation inhibitor 1-14%, biocompatible polymer matrix 70-92%; Smegglutinin 3-7%, acylation inhibitor 2-10%, biocompatible polymer matrix 70-92%; Smegglutinin 3-6%, acylation inhibitor 2-10%, biocompatible polymer matrix 80-92%; Smegglutinin 3-10%, hydroxyethyl starch 0.3-30%, PLGA 65-95%; Smegglutinin 3-7%, hydroxyethyl starch 1-14%, PLGA 70-92%; Smegglutinin 3-7%, hydroxyethyl starch 2-10%, PLGA 70-92%; Smegglutinin 3-6%, hydroxyethyl starch 1-14%, PLGA 80-92%; Smegglutinin 3-6%, hydroxyethyl starch 2-10%, PLGA 80-92%; Smegglutinin 3-6%, hydroxyethyl starch 4-9.5%, PLGA 80-92%; Smegglutinin 3-10%, histidine 0.3-8%, poloxamer 0.3-8%, PLGA 65-95%; Smegglutinin 3-7%, histidine 1-5%, poloxamer 1-5%, PLGA 70-92%; Smegglutinin 3-7%, histidine 1-5%, poloxamer 1.5-5%, PLGA 80-92%; Smegglutinin 3-6%, histidine 0.3-8%, poloxamer 0.3-8%, PLGA 65-95%; Smegglutinin 3-6%, histidine 1-5%, poloxamer 1-5%, PLGA 70-92%; Smegglutinin 3-6%, histidine 1-5%, poloxamer 1.5-5%, PLGA 80-92%; Smegglutide 3-10%, dextran 0.3-30%, PLGA 65-95%; Smegglutinin 3-7%, dextran 1-14%, PLGA 70-92%; Smegglutinin 3-7%, dextran 2-10%, PLGA 70-92%; Smegglutinin 3-6%, dextran 1-14%, PLGA 80-92%; Smegglutinin 3-6%, dextran 2-10%, PLGA 80-92%; Smegglutide 3-6%, dextran 4-9.5%, PLGA 80-92%; Smegglutide 3-10%, histidine 0.3-8%, poloxamer 0.3-8%, dextran 0.3-8%, PLGA 65-95%; Smegglutide 3-7%, histidine 1-5%, poloxamer 1-5%, dextran 2-10%, PLGA 70-92%; Smegglutide 3-6%, histidine 1-5%, poloxamer 1.5-5%, dextran 2-7%, PLGA 80-92%; Smegglutide 5.7%, acylation inhibitor 5.7%, PLGA 88.6%; Smegglutide 5.8%, acylation inhibitor 3.9%, PLGA 90.3%; Smegglutide 4.6%, acylation inhibitor 9.3%, PLGA 86.1%; Smegglutinin 4.6%, hydroxyethyl starch 9.3%, PLGA 86.1%; Smegglutide 4.6%, dextran 9.3%, PLGA 86.1%; Smegglutide 5.7%, dextran 5.7%, PLGA 88.6%; Smegglutinin 5.8%, L-histidine 1.6%, poloxamer 2.3%, PLGA 90.3%; Each is based on the total weight of the injectable polypeptide sustained-release microsphere composition.
9. A sterile microsphere product comprising an injectable polypeptide sustained-release microsphere composition according to any one of claims 1 to 8 and a desiccant, wherein the desiccant is selected from mannitol, sorbitol, lactose, trehalose, and polyethylene glycol, preferably mannitol.
10. The sterile microsphere product according to claim 9, characterized in that, The amount of the desiccant is 10-30% of the mass of the injectable polypeptide sustained-release microsphere composition, preferably 15-25%, and more preferably 18-22%.
11. The sterile microsphere product according to claim 9 or 10, characterized in that, The particle size D50 of the sterile microsphere product is 10~150 μm, preferably 20~130 μm, more preferably 30~110 μm, even more preferably 40~90 μm, and most preferably 50~70 μm; the encapsulation rate is 75~99%.
12. A polypeptide sustained-release microsphere composition for injection, characterized in that, It is prepared by a method including the following steps: A) Dissolve semaglutide and acylation inhibitor in water to form a true solution; B) Dissolve the biocompatible polymer matrix in an organic solvent to form an oil phase solution, and then add the true solution obtained in step A) to the oil phase solution, and process it to form a heterogeneous solution; C) Add a phase-separating agent to the heterogeneous solution obtained in step B), form a phase-separated phase under stirring conditions, and transfer the phase-separated phase to a solidification system for solidification and washing to obtain wet microspheres; D) The microsphere wet product obtained in step C) is dried at a controlled temperature to obtain a polypeptide sustained-release microsphere composition; The method uses 2-15% smegglutinin, 0.3-30% acylation inhibitor, and 55-97% biocompatible polymer matrix, based on the total weight of the three components.
13. A sterile microsphere product comprising an injectable polypeptide sustained-release microsphere composition and a desiccant, characterized in that, It is prepared by the following steps: mixing the injectable polypeptide sustained-release microsphere composition of claim 12 with a drying protectant; The amount of drying and protective agent used in the powder mixing step is 10-30% of the mass of the injectable polypeptide sustained-release microsphere composition, preferably 15-25%, and more preferably 18-22%.
Citation Information
Patent Citations
Compositions of GLP-1 peptides and preparation thereof
CN104203266A
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN105963685A
Method for inhibiting acylation side reaction of polypeptide drugs in PLGA microspheres
CN110090293A
Sustained release preparation for injection and preparation method thereof
CN116473909A
